Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.34 |
| ▸ | PDE2A | O00408 | 4/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973529 | 0.91 | LTA4H (0.39) | PDE3BPDE3AP2RY12PDE2ALTA4H | |
| SCHEMBL525935 | 0.90 | PDE3B (0.39) | FFAR1PDE3BPDE3AP2RY12LTA4H | |
| SCHEMBL530478 | 0.88 | PDE3B (0.35) | PDE3BPDE3AP2RY12LNPEPLTA4H | |
| SCHEMBL14973551 | 0.84 | KDM4E (0.44) | PDE3BPDE3AKDM4E | |
| SCHEMBL525916 | 0.79 | PDE3B (0.39) | PDE3BPDE3AP2RY12KDM4ELTA4H | |
| SCHEMBL14973639 | 0.78 | PDE3B (0.34) | FFAR4FFAR1PDE3BPDE3AP2RY12 | |
| SCHEMBL525627 | 0.77 | DYRK1A (0.37) | PDE3BPDE3AP2RY12PDE2AKDM4E | |
| SCHEMBL14973627 | 0.75 | KDM4E (0.41) | PDE3BPDE3AKDM4E | |
| SCHEMBL2492660 | 0.74 | DYRK1A (0.46) | PDE3BPDE3AP2RY12PDE2AKDM4E | |
| SCHEMBL1437810 | 0.72 | KDM4E (0.34) | KDM4ELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, TP53, MYC | FFAR4 4649/4885FFAR1 4517/4885PDE3B 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.